HK Stock Market Move | BIOCYTOGEN-B(02315) contrary to the trend, rose more than 10%. The localization deployment of the AI-driven antibody drug research platform DeepSeek has been completed.

BIOCYTOGEN-B (02315) rose by over 10% against the market trend, rising by 10.07% to HK$12.02 as of the time of writing, with a turnover of HK$125,200. On the news front, BIOCYTOGEN-B announced that the company has recently completed the localization deployment of the artificial intelligence (AI)-driven antibody drug research platform DeepSeek, and has achieved comprehensive coordination with the company's core business "Thousand Mice, Ten Thousand Antibodies" plan. This technical integration signifies a new stage of intelligence and data-driven antibody drug early-stage research, which will provide more precise and breakthrough antibody drug research solutions for global pharmaceutical companies in the future, greatly accelerating the drug development process. According to reports, By-Health, through the combination of the "Thousand Mice, Ten Thousand Antibodies" antibody molecular library and the DeepSeek platform, can provide global pharmaceutical companies with new single, double, and multiple antibody molecular frameworks. These molecular frameworks have high affinity, low immunogenicity, and excellent drug-like properties. With the DeepSeek platform, global pharmaceutical companies can quickly screen out target antibody molecules with extremely high drug potential from the existing million-level antibody molecular library of "Thousand Mice, Ten Thousand Antibodies". DeepSeek can also use simulated molecular interactions to screen and obtain molecular frameworks from the huge antibody molecular library of "Thousand Mice, Ten Thousand Antibodies" and rapidly design multi-specific antibodies with specific functions, such as double antibodies and multiple antibodies, to rapidly develop innovative antibody drugs for various diseases, greatly accelerating the drug development process and meeting unmet clinical needs.